Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17909367 | 1.00 | CYP1A2 (0.52) | CYP1A2DGKANR1I2PGRADORA3 | |
| SCHEMBL17909012 | 1.00 | CYP1A2 (0.52) | CYP1A2DGKANR1I2PGRADORA3 | |
| SCHEMBL8269055 | 0.93 | DGKA (0.48) | CYP1A2DGKANR1I2PGRADORA3 | |
| SCHEMBL17450347 | 0.93 | DGKA (0.48) | CYP1A2DGKANR1I2PGRADORA3 | |
| SCHEMBL13226673 | 0.93 | DGKA (0.48) | CYP1A2DGKANR1I2PGRADORA3 | |
| SCHEMBL3627923 | 0.93 | DGKA (0.48) | CYP1A2DGKANR1I2PGRADORA3 | |
| SCHEMBL14010969 | 0.93 | DGKA (0.48) | CYP1A2DGKANR1I2PGRADORA3 | |
| SCHEMBL907371 | 0.90 | CYP1A2 (0.61) | CYP1A2DGKANR1I2PGRADORA3 | |
| SCHEMBL17908601 | 0.88 | CYP1A2 (0.55) | CYP1A2DGKANR1I2PGRADORA3 | |
| SCHEMBL15010581 | 0.88 | CYP1A2 (0.45) | CYP1A2DGKANR1I2PGRADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105801686-B | Insulin-oligomer conjugates, formulations and uses thereof | 比奥孔有限公司 | 2020-04-07 | — | — | CN | disclosed |
| EP-3048093-B1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | MORESCO CORP (JP) | 2019-02-20 | — | — | EP | disclosed |
| US-10077229-B2 | Ether-containing monoester compound and use thereof | MORESCO CORPORATION (JP) | 2018-09-18 | — | — | US | disclosed |
| EP-2626368-B1 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LTD (IN) | 2016-12-21 | — | — | EP | disclosed |
| EP-3048093-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | Moresco Corporation (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20160200998-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | MORESCO CORPORATION (JP) | 2016-07-14 | — | — | US | disclosed |
| CN-105579431-A | Ether-containing monoester compound and use thereof | MORESCO CORP | 2016-05-11 | — | — | CN | disclosed |
| US-9101596-B2 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9101596-B2 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9102758-B2 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2010-04-29 | — | — | US | disclosed |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2010-04-29 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| EP-1773878-A2 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | Nobex Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014673-A2 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | NOBEX CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060018874-A1 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060019873-A1 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060019874-A1 | Cation complexes of insulin compund conjugates, formulation and uses thereof | NOBEX CORPORATION | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019873-A1 | Cation complexes of insulin compound conjugates, formulations and uses thereof | GPR119, INSR, IAPP | CYP1A2 3213/4885DGKA 2390/4885NR1I2 1645/4885 |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | FABP2, SLC27A1, SLC27A2 | CYP1A2 2868/4885DGKA 1422/4885NR1I2 3635/4885 |
| US-20060018874-A1 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | FABP2, SLC27A1, SLC27A2 | CYP1A2 2866/4885DGKA 1422/4885NR1I2 3634/4885 |
| US-20060019874-A1 | Cation complexes of insulin compund conjugates, formulation and uses thereof | INSR, GPR119, IAPP | CYP1A2 3781/4885DGKA 2461/4885NR1I2 1802/4885 |
| US-10077229-B2 | Ether-containing monoester compound and use thereof | SFN, CCNE2, HSD3B2 | CYP1A2 382/4885DGKA 1202/4885NR1I2 840/4885 |
| US-20160200998-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | SFN, CCNE2, MSMO1 | CYP1A2 403/4885DGKA 1333/4885NR1I2 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.